On the stock market since 2024, it operates in the world of health and science. It has 2 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $32K a year. A small number, but proof the product has real buyers.
A loss of $11.8M against $32K in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.44. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.7 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, IBO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IBO is a high-risk stock — not yet profitable, and its future rides on its product catching on.